KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Alnylam Pharmaceuticals (ALNY) Debt to Equity (2016 - 2025)

Alnylam Pharmaceuticals (ALNY) has disclosed Debt to Equity for 7 consecutive years, with $0.48 as the latest value for Q2 2025.

  • For the quarter ending Q2 2025, Debt to Equity changed N/A year-over-year to $0.48, compared with a TTM value of $0.48 through Jun 2025, changed N/A, and an annual FY2024 reading of $1.4, changed N/A over the prior year.
  • Debt to Equity was $0.48 for Q2 2025 at Alnylam Pharmaceuticals, down from $1.02 in the prior quarter.
  • Across five years, Debt to Equity topped out at $1.4 in Q4 2024 and bottomed at $0.48 in Q2 2025.
  • Average Debt to Equity over 3 years is $1.01, with a median of $1.09 recorded in 2021.
  • Peak annual rise in Debt to Equity hit 510.32% in 2021, while the deepest fall reached 510.32% in 2021.
  • Year by year, Debt to Equity stood at $1.15 in 2021, then rose by 21.71% to $1.4 in 2024, then tumbled by 65.52% to $0.48 in 2025.
  • Business Quant data shows Debt to Equity for ALNY at $0.48 in Q2 2025, $1.02 in Q1 2025, and $1.4 in Q4 2024.